15,486 Shares in Boston Scientific Corporation $BSX Bought by Stoneridge Investment Partners LLC

Stoneridge Investment Partners LLC purchased a new stake in shares of Boston Scientific Corporation (NYSE:BSX) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 15,486 shares of the medical equipment provider’s stock, valued at approximately $724,000.

Several other institutional investors have also added to or reduced their stakes in BSX. Vanguard Group Inc. grew its stake in shares of Boston Scientific by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock worth $13,319,060,000 after purchasing an additional 1,436,550 shares during the last quarter. State Street Corp raised its position in Boston Scientific by 1.4% during the 4th quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock valued at $6,278,422,000 after purchasing an additional 920,495 shares during the last quarter. Capital World Investors raised its position in Boston Scientific by 1.9% during the 4th quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock valued at $2,588,953,000 after purchasing an additional 502,627 shares during the last quarter. Norges Bank purchased a new stake in Boston Scientific in the 4th quarter worth approximately $2,199,395,000. Finally, Morgan Stanley lifted its stake in Boston Scientific by 10.8% in the fourth quarter. Morgan Stanley now owns 22,960,556 shares of the medical equipment provider’s stock worth $2,189,289,000 after acquiring an additional 2,246,308 shares during the period. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Insider Buying and Selling at Boston Scientific

In related news, Director David C. Habiger purchased 2,250 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The shares were bought at an average price of $55.92 per share, for a total transaction of $125,820.00. Following the purchase, the director directly owned 13,878 shares of the company’s stock, valued at approximately $776,057.76. This represents a 19.35% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Michael F. Mahoney acquired 186,240 shares of Boston Scientific stock in a transaction that occurred on Monday, August 3rd. The shares were bought at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the transaction, the chief executive officer owned 1,590,024 shares in the company, valued at $76,845,859.92. This represents a 13.27% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders acquired a total of 204,322 shares of company stock worth $9,939,221 over the last three months. Company insiders own 0.34% of the company’s stock.

Boston Scientific Stock Up 0.1%

NYSE:BSX opened at $51.77 on Friday. The firm’s 50-day moving average price is $46.06 and its 200-day moving average price is $59.35. The company has a market capitalization of $75.02 billion, a PE ratio of 20.96, a P/E/G ratio of 1.13 and a beta of 0.56. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. Boston Scientific Corporation has a 1-year low of $42.20 and a 1-year high of $109.50.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The company had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. During the same period last year, the company posted $0.75 EPS. Boston Scientific’s revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, equities analysts predict that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific declared that its Board of Directors has authorized a stock repurchase plan on Monday, May 18th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s board of directors believes its shares are undervalued.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: An investment analysis argues that Boston Scientific could recover from its recent headwinds, supporting the view that the company’s diversified portfolio and structural-growth markets can reaccelerate over time. Boston Scientific: A Deep Dive Into The Headwinds And Why I See A Recovery Ahead
• Positive Sentiment: Analyst consensus remains broadly favorable, with brokerage recommendations suggesting that BSX may merit portfolio consideration. However, the article cautions that sell-side ratings can be overly optimistic and should not be used as the sole investment signal. Brokers Suggest Investing in Boston Scientific
• Neutral Sentiment: Recent fund commentary highlights Boston Scientific’s second-quarter performance and the factors that affected the stock, giving investors additional context on the company’s operating challenges but offering no new company guidance or specific catalyst. Here’s What Hurt Boston Scientific Corporation in Q2
• Negative Sentiment: Parnassus Investments identified a growth slowdown in key Boston Scientific businesses. That raises concerns about near-term revenue momentum and could pressure the stock if weaker growth persists, despite the company’s recent earnings beat and positive longer-term outlook. Boston Scientific Faces Growth Slowdown in Key Businesses

Analysts Set New Price Targets

Several equities analysts recently issued reports on BSX shares. Wells Fargo & Company reduced their price target on shares of Boston Scientific from $55.00 to $50.00 and set an “equal weight” rating on the stock in a research report on Thursday, July 30th. Bank of America lowered their price objective on shares of Boston Scientific from $105.00 to $68.00 and set a “buy” rating for the company in a report on Monday, May 18th. Wall Street Zen cut Boston Scientific from a “buy” rating to a “hold” rating in a research report on Sunday, August 2nd. The Goldman Sachs Group set a $71.00 target price on Boston Scientific in a report on Thursday, May 28th. Finally, TD Cowen decreased their target price on Boston Scientific from $61.00 to $56.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Twenty-four research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $71.62.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.